Comcast, Viridian Therapeutics jump premarket; Doximity slips
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Viridian Therapeutic (VRDN) PT Raised to $43 at Wedbush
June 29, 2026 12:25 PM EDTWedbush analyst Laura Chico raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $43.00 (from $32.00) while maintaining a Outperform rating.
The analyst comments "Remain Outperform rated on VRDN, new $43 target. Most notable on the VRDN investor call, management confirmed the Lumvoa price... More
William Blair on Viridian Therapeutic (VRDN): 'We came away from the call incrementally more confident'
June 29, 2026 12:25 PM EDTWilliam Blair analyst Lachlan Hanbury-Brown reiterated an Outperform rating on Viridian Therapeutic (NASDAQ: VRDN)
The analyst comments "On Monday, June 29, Viridian hosted a call to discuss the approval and commercial launch of Lumvoa (veligrotug-vvze) for the treatment of thyroid eye disease (TED).... More
